期刊
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
卷 490, 期 2, 页码 486-491出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2017.06.067
关键词
Amyloid-beta protein precursor; Alzheimer's disease; O-GlcNAcylation; Amyloid
资金
- Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education, Science and Technology [2016R1D1A1A099]
- National Research Foundation of Korea [2016R1D1A1A09919505] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The pathological hallmark of Alzheimer's disease (AD) is associated with the accumulation of amyloid-beta (AP) derived from proteolytic processing of amyloid-beta precursor protein (APP). APP undergoes post translational modification including N- and O-glycosylation. O-GIcNAcylation is a novel type of O-glycosylation, mediated by O-GIcNAc transferase attaching O-beta-N-acetylglucosamine (O-GIcNAc) to serine/threonine residues of the target proteins. O-GIcNAc is removed by O-GlcNAcase. We have previously reported that increasing O-GIcNAcylated APP using the O-GIcNAcase inhibitor, PUGNAc, increases its trafficking rate to the plasma membrane and decreases its endocytosis rate, resulting in decreased AP production. However, O-GIcNAc modification sites in APP are unknown. In this study, we mutated three predicted O-GIcNAc modification threonine residues of APP into alanines (T291A, T292A, and T576A) and expressed them in HeLa cells. These APP mutants showed reduced O-GIcNAcylation levels, indicating that these sites were endogenously O-GIcNAcylated. Thr 576 was the major O-GIcNAcylation site when cell was treated with PUGNAc. We also showed that the effects of PUGNAc on APP trafficking to the plasma membrane and AP production were prevented in the T576A mutant. These results implicate Thr 576 as the major O-GIcNAcylation site in APP and indicate that O-GIcNAcylation of this residue regulates its trafficking and processing. Thus, specific O-GIcNAcylation of APP at Thr 576 may be a novel and promising drug target for AD therapeutics. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据